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Background: The Orsiro Hybrid sirolimus-eluting stent is a newly developed third-generation drug-eluting stent,
featuring a unique dual-polymer mix. An active bioabsorbable polymer delivers the anti-proliferative drug, sirolimus,
via controlled release, while a passive biocompatible polymeric coating shields the metallic strut from surrounding
tissue, preventing interaction. To date, the Orsiro Hybrid sirolimus-eluting stent has excelled in terms of late lumen loss
at 9 months in a first-in-man single-arm trial. However, the efficacy and safety data for Orsiro Hybrid sirolimus-eluting
stents in a broader population of all-comers are limited. The present study offers an angiographic and clinical
comparison of the Orsiro Hybrid sirolimus-eluting stent and the Resolute Integrity zotarolimus-eluting stent in
the treatment of patients with coronary artery disease.
Methods/design: The ORIENT trial is a multicenter, randomized, open-label, parallel-arm study designed to
demonstrate the non-inferiority of the Orsiro Hybrid sirolimus-eluting stent relative to the Resolute Integrity
zotarolimus-eluting stent. A total of 375 patients with a spectrum of coronary artery disease will undergo prospective,
random assignment to a Orsiro Hybrid sirolimus-eluting stent or Resolute Integrity zotarolimus-eluting stent (2:1 ratio),
for a primary endpoint of in-stent late lumen loss at 9 months by quantitative coronary angiography. Secondary
12-month clinical endpoints are death, target lesion revascularization, target vessel revascularization, myocardial
infarction, stent thrombosis and target lesion failure (a composite of cardiac death, target lesion revascularization
and target vessel-related myocardial infarction).
Discussion: The ORIENT trial is the first study to date comparing the Orsiro Hybrid sirolimus-eluting stent with
the Resolute Integrity zotarolimus-eluting stent for efficacy and safety in a population of all-comers with coronary
artery disease.
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Figure 1 ORIENT trial algorithm. ACC, American College of
Cardiology; AHA, American Heart Association; CAG, coronary
angiography; DES, drug-eluting stent; ESC, European Society of
Cardiology; EACTS, European Association for Cardio-Thoracic Surgery;
F/U, follow-up; QCA, quantitative coronary angiography; SCAI, The
Society for Cardiovascular Angiography and Interventions; SES,
sirolimus-eluting stent; ZES, zotarolimus-eluting stent.
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Since the introduction of the first-generation drug-eluting
stent (DES), rates of restenosis after percutaneous coronary
intervention (PCI) have declined dramatically [1-3].
However, there are concerns that the benefit of a DES
in reducing restenosis is at the expense of thrombo-
genic risk. Hence, efforts to reduce both restenosis and
thrombosis are ongoing and have resulted in a flurry of
second-generation devices made with biocompatible
but non-absorbable polymers, as well as third-generation
models incorporating bioabsorbable polymers [4,5].
The recently launched Orsiro Hybrid sirolimus-eluting
stent (Orsiro SES, Biotronik AG, Bulach, Switzerland)
features a unique hybrid polymer laminate over thin
cobalt chromium struts. The active BIOlute® bioabsorbable
polymer matrix is embedded with the anti-proliferative
drug sirolimus and releases the drug in a controlled
manner after implantation. This component degrades
over time, leaving behind only the PROBIO® encapsulated
stent. The passive PROBIO® coating confers a protective
interface that guards against a reaction between the
stent’s metal framework and the surrounding tissues
[6]. Although the Orsiro SES has excelled in terms of
late lumen loss at 9 months in a first-in-man single-arm
trial (BIOFLOW-I trial) [7], randomized controlled trials
evaluating its efficacy and safety are limited to date.
The ORIENT Trial will be an angiographic and clinical
comparison of the Orsiro SES, an innovative third-
generation DES, with the Resolute Integrity zotarolimus-
eluting stent (ZES-I, Medtronic Cardiovascular, Santa
Rosa, CA, USA), the latest second-generation DES, in the
treatment of patients with coronary artery disease (CAD).
Methods/design
Study design
This is a prospective, randomized, open-label, and parallel-
group multicenter trial designed to test the non-inferiority
of the Orsiro SES relative to the ZES-I in preventing late
lumen loss 9 months after the index procedure (Figure 1).
A total of 375 patients exhibiting a wide spectrum of
CAD will be enrolled at eight centers in Korea. Participants
will be monitored clinically at months 1, 6, 9 and 12.
Investigators may conduct this follow-up as telephone
interviews or office visits. An angiographic follow-up to
determine late lumen loss is advised at 9 months post-
procedure or earlier should the patient experience ische-
mic symptoms or show non-invasive evidence of ischemia.
This trial is investigator-initiated, with grant support
from the Biotronik Korea Co, Korea. Other than financial
sponsorship, the company has no role in protocol
development or the implementation, management, data
collection and analysis of this study. The authors alone
are responsible for the design and execution of the trial,
related statistical analyses and all aspects of manuscriptpreparation, including drafting, editing and final content.
This study will be conducted according to the principles
outlined in the Declaration of Helsinki. All patients must
provide written informed consent. This study protocol has
been approved by the institutional review board of Seoul
National University Bundang Hospital and registered at
www.clinicaltrials.gov (NCT01826552).
Study population and entry criteria
Prospective subjects are those at least 18 years of age,
presenting with symptomatic CAD (including acute
coronary syndrome) and coronary lesions >50%, in whom
PCI with DES implantation is indicated, based on the
current recommendations of ACC/AHA/SCAI and ESC/
EACTS guidelines or the clinical judgment of the inter-
ventional cardiologist (Table 1) [8,9]. Whether the PCI is
indicated based on current recommendations or not will
be separately recorded. Inclusion and exclusion criteria
will be graded to minimize exclusion of patients, thus
reflecting the population at large. All participants will
be randomly assigned in a 2:1 ratio to either the Orsiro
SES or ZES-I group. To generate comparable groups
relative to known and unknown risk factors, randomization
will be independently conducted online via a web-based
application (T&W Software, Seoul, Korea). The random-
ization will be balanced and stratified by participating
center and allocated treatment groups.
Outcome measurements and definitions
The primary endpoint of the trial is in-stent late lumen
loss at 9 months, as measured by quantitative coronary
angiography (QCA). Secondary angiographic endpoints
Table 1 Eligibility criteria for the ORIENT trial
Inclusion criteria
● Patient age ≥18 years
● Ability to acknowledge verbally the risks, benefits and treatment ramifications in receiving the Orsiro Hybrid®
or Resolute Integrity® stent
● Written informed consent given by legally authorized agent prior to any study-related procedure
● Indication for use of drug-eluting stent based on ACC/AHA/SCAI and ESC/EACTS guidelines and/or clinical
judgment of interventional cardiologist.
● Target lesion(s) in coronary artery or graft vessel with estimated reference diameter ≥2.5 mm and ≤5.0 mm
● Target lesion(s) amenable to percutaneous coronary intervention
Exclusion criteria
● Known hypersensitivity or contraindication to any of the following agents: heparin, aspirin, clopidogrel, sirolimus,
zotarolimus, cobalt chromium or contrast mediaa
● Inability to tolerate aspirin or clopidogrel for 1-year duration of study
● Systemic (intravenous) use of sirolimus or zotarolimus within 12 months
● Females with childbearing potential (unless negative by a recent pregnancy test) or anticipating pregnancy following study enrollment
● History of bleeding diathesis, known coagulopathy (including heparin-induced thrombocytopenia), or refusal of blood transfusions
● Gastrointestinal or genitourinary bleeding within prior 3 months, or major surgery within 2 months
● Planned major non-cardiac surgery within designated study period
● Cardiogenic shock (Killip class IV)
● Symptomatic heart failure, precluding coronary angiography in a supine position
● Non-cardiac co-morbid conditions limiting life expectancy (to <1 year) or potentially undermining protocol compliance
(as judged by the site investigator)
● Active participation in another drug- or device-related investigational study where the primary endpoint follow-up is ongoing
● Unwillingness or inability to comply with protocol procedures
aPatients with documented sensitivity (such as a rash) to contrast media that is amenable to premedication with steroids and diphenhydramine may still be
enrolled. However, true anaphylaxis on prior exposure to contrast media is grounds for exclusion.
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diameter stenosis (%DS) and binary restenosis. Secondary
clinical endpoints include all-cause and cardiac deaths,
clinically driven target lesion revascularization (TLR),
target vessel revascularization (TVR), myocardial infarction
(MI) (target or non-target vessel-related), stent thrombosis
and target lesion failure (TLF, a composite of cardiac death,
TLR and target vessel-related MI) at 12 months [10,11].
Revascularization is considered clinically driven if the
follow-up angiographic diameter stenosis ≥50%, and
there is at least one of the following: (1) history of
recurrent angina pectoris, presumably related to the
target vessel, (2) objective signs of ischemia at rest or
during exercise testing (or equivalent), presumably due
to the target vessel, (3) abnormal invasive functional
diagnostic testing or (4) TLR or TVR with ≥70% diameter
stenosis, even without any of the aforementioned ischemic
signs/symptoms [10,12].
To reduce the chance of the so-called oculostenotic
reflex, whereby rates of repeated revascularization are
disproportionately high, investigators will be encouraged
to perform a non-invasive stress test or invasive functional
diagnostic test (for example, fractional flow reserve) prior
to a decision regarding repeated revascularization and they
will adhere strictly to a clinically driven revascularizationprotocol. In addition, the specified indication of revas-
cularization and the number of TVRs or TLRs that are
performed without a non-invasive stress test will be
separately recorded.
Coronary angiography and percutaneous coronary
intervention
Coronary interventions will be performed according to
current standard techniques. Aside from random stent
assignment, any pre-dilatation, post-stenting adjunctive
balloon inflation, and intravascular ultrasound or glyco-
protein IIb/IIIa inhibitor use will be at the operators'
discretion. All patients will receive aspirin (300 mg)
and a loading dose of clopidogrel (300 mg to 600 mg)
prior to the procedure, unless these are routinely taken,
for at least 1 week beforehand. Heparin sufficient to
sustain activated clotting time at >250 sec will be
administered intravenously in boluses during the pro-
cedure. All patients will be given aspirin indefinitely (at
least 100 mg/day) and clopidogrel (75 mg/day) for a
minimum of 12 months after the index procedure.
Quantitative coronary angiography
The coronary angiography at baseline, immediately after
the procedure and at follow-up will be analyzed using
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Angiography Analysis System 5.7.1; Pie Medical Imaging
Systems, Maastricht, the Netherlands) at the core labora-
tory in Seoul National University Bundang Hospital by
an experienced technician who is blinded to the study.
The minimal lumen diameter (MLD), reference vessel
diameter, %DS, acute gain (difference in MLD pre- and
post-implantation of the stent), late lumen loss (difference
in post-procedural and follow-up MLD) and binary re-
stenosis (≥50% stenosis at the follow-up angiography)
will be measured [13]. All QCA assessments of target
lesions will be in-stent and in-segment (stent plus 5-mm
proximal and distal margins).
Statistical considerations
Sample size calculation
To test the primary hypothesis (non-inferiority of the
Orsiro SES relative to the ZES-I by 9-month in-stent late
lumen loss), we assumed a mean late loss of 0.3 mm (SD
0.54 mm) for both stents, which was extrapolated from
the QCA results for the Endeavor Resolute® (ZES-R)
from the RESOLUTE US trial [14]. The ZES-I and ZES-R
devices use same the delivery drug (zotarolimus) and
basic design, namely a biocompatible polymer (BioLinx®)
mounted on a cobalt chromium platform. For non-
inferiority testing, with a 0.2 mm non-inferiority margin,
type I error at 0.05 (one-sided), 90% statistical power,
2:1 sampling ratio (Orsiro SES:ZES-I) and an expected
30% dropout rate (at the 9-month follow-up angiog-
raphy), a total of 375 patients (Orsiro SES, 250; ZES-I,
125) were deemed necessary to execute this study. To
avoid interlesion clustering of restenosis in patients
receiving stents for multiple lesions, which would have
required correction with multilevel generalized estimating
equations, only one randomly selected lesion will be
used in the analysis of in-stent late lumen loss [15,16].
Sequential superiority testing will be performed if non-
inferiority for in-stent late lumen loss is met. This
number of patients would also have 92% power to
detect superiority with an in-stent late lumen loss
difference of 0.2 mm between the groups at a two-sided
alpha level of 0.05.
Statistical analysis
All primary and secondary endpoints will first be analyzed
on an intention-to-treat basis (all patients according to
the assigned treatment groups), and secondarily, per
protocol/treatment. The per protocol analysis is aimed
at patients completing the study protocol as initially
assigned, without significant breach or crossover, whereas
the per treatment analysis addresses the treatment mo-
dality received, regardless of initial device assignment.
Per protocol/treatment analyses are intended solely for
descriptive comparisons, not as tests of the workinghypothesis. For the intention-to-treat analysis, all patients
giving written informed consent and randomly assigned
for the study will be used in the analysis sample, whether
or not the treatment rendered was correct or crossover
occurred. The endpoints will also be subjected to per
patient and per lesion analyses as feasible.
The null hypothesis will be evaluated on a non-
inferiority basis, using an independent sample t-test of the
mean late lumen loss in both groups. Non-inferiority is
defined by a one-sided alpha of 5% and a difference in
late lumen loss ≤0.2 mm. TLF, TLR, TVR, MI and stent
thrombosis rates at 12 months will be analyzed with a
χ2-test, generating Kaplan–Meier survival estimates for
time to events of TLF, TLR, TVR and MI at 12 months.
Acute success (device, lesion and procedure) analysis
will utilize a χ2-test as specified. An independent t-test
or χ2-test will be invoked as needed to assess in-stent/
in-segment %DS and in-stent/in-segment binary restenosis
at 9 months. In addition, exploratory subgroup analysis
will be performed, rather than pre-specified subgroup
analysis.
Study organization and ethical consideration
The principal investigator, the study coordinator, and
the Clinical Trials Center at Seoul National University
Bundang Hospital are jointly responsible for all aspects
of the study protocol and amendments. Site monitoring
and data collection will be performed by a dedicated
affiliated research coordinator. At appropriate intervals,
designated trial monitors will review all investigational
data for accuracy and completeness to ensure protocol
compliance. In addition to the executive committee, the
steering committee, data safety and monitoring board and
the clinical event adjudication committee will be involved
for the duration of the trial.
Discussion
The first-generation of DESs, armed with sirolimus or
paclitaxel, was shown to reduce in-stent neointimal
hyperplasia, reduce rates of clinical restenosis and curtail
the need for repeated PCI, compared with bare metal
stents [17,18]. However, the greater risk of late stent
thrombosis raised safety concerns [17]. A number of
mechanisms were thought responsible for the thrombotic
proclivity of DES-treated arterial segments. In particular,
the suboptimal biocompatibility of polymers coating
the bulky stainless steel alloy of first-generation devices
was held culpable for delayed endothelialization and
hypersensitivity reactions [19]. DES-related research and
development subsequently embraced long-term safety as
well as performance enhancement.
Second-generation devices were thus developed using
breakthrough technology, such as thinner stent struts,
permanent but biocompatible polymers to minimize
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anti-proliferative agents. The ZES family and the evero-
limus-eluting stent (EES) are second-generation DES
prototypes. They are fabricated with cobalt chromium alloy,
which imparts superior radial strength and radiopacity.
The thinner struts dampen the neointimal response
and promote more rapid re-endothelialization [19]. The
biocompatible polymers, when coupled with newer anti-
proliferative agents, likewise improved drug delivery,
reducing neointimal proliferation and causing fewer
thrombotic events than older devices [4,5].
In contrast, third-generation devices now incorporate
biocompatible polymers, which gradually degrade after
implantation. The potential for a late inflammatory reaction
due to a non-absorbable polymer is thus avoided, and
the subsequent risk of late or very late stent thrombosis
is reduced [20]. The Orsiro SES features a hybrid of active
and passive polymers, which is unique in its class. Its
active BIOlute® coating is made of poly-L-lactide, a
well-characterized bioabsorbable polymer, which gives
a controlled drug release. The sirolimus drug load is
1.4 μg/mm2 and 50% of the drug is released within 30
days and 80% within 3 months. The passive PROBIO®
polymer seals the stent surface, reducing the interaction
between the metal framework and surrounding tissue
and forming a diffusion barrier for blood. Inherent
biocompatibility is thereby improved, which reduces
thrombogenicity and facilitates re-endothelialization [6].
In addition to advanced encapsulation, the Orsiro SES
has a thinner cobalt chromium-based strut (60 μm)
than its DES forerunners (ZES-R, 91 μm; EES, 81 μm).
Even with the added polymer coating, the total strut
thickness is only 71 μm (for a 3.0-mm stent), which is
significantly thinner than comparators (ZES-R, 99 μm;
EES, 95 μm). The Orsiro SES has shown promise in
terms of late lumen loss at 9 months in a first-in-man
single-arm trial, and the BIOFLOW-II trial, comparing
9-month late lumen loss of the Orsiro SES with EES, is
ongoing [7]. However, a comparison of the Orsiro SES
with ZES-I, the latest second-generation DES, has not
been done to date. We expect this study to provide
valuable data on the therapeutic outcomes of second- and
third-generation DES devices.
Trial status
The ORIENT trial has begun patient randomization in
October 2013. The principal investigator may be contacted
by email.
Abbreviation
%DS: Percentage diameter stenosis; CAD: Coronary artery disease; CAG: Coronary
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MI: Myocardial infarction; MLD: Minimum lumen diameter; PCI: Percutaneous
coronary intervention; QCA: Quantitative coronary angiography; SES:
Sirolimus-eluting stent; TLR: Target lesion revascularization; TVR: Target vessel
revascularization; ZES-I: Resolute integrity zotarolimus-eluting stent.Competing interests
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